P05-05. Enhanced immunogenicity of HIV-1 envelope glycoprotein trimers fused to CD40 ligand

doi:10.1186/1742-4690-6-S3-P81

Retrovirology

Volume 6
Suppl 3

Viewing options:

Abstract
Full text
PDF (130KB)

Related literature:

Articles citing this article
on Google Scholar
Other articles by authors
on Google Scholar

Melchers M
Matthews K
van Montfort T
Bontjer I
Eggink D
de Vries R
Michael E
David K
Moore JP
Berkhout B
Sanders RW

on PubMed

Melchers M
Matthews K
van Montfort T
Bontjer I
Eggink D
de Vries R
Michael E
David K
Moore JP
Berkhout B
Sanders RW
Related articles/pages
on Google

on Google Scholar

Tools:

Post to:

This article is part of the supplement: AIDS Vaccine 2009 .

Poster presentation

P05-05. Enhanced immunogenicity of HIV-1 envelope glycoprotein trimers fused to CD40 ligand

M Melchers¹, K Matthews², T van Montfort¹, I Bontjer¹, D Eggink¹, R de Vries¹, E Michael², K David², JP Moore², B Berkhout¹ and RW Sanders²

¹Academic Medical Center, Amsterdam, Netherlands

²Microbology and Immunology, Weill Medical College of Cornell University, New York, USA

corresponding author email

from AIDS Vaccine 2009
Paris, France. 19–22 October 2009

Retrovirology 2009, 6(Suppl 3):P81doi:10.1186/1742-4690-6-S3-P81


Published:	22 October 2009

First paragraph (this article has no abstract)

Subunit vaccines are often poor immunogens compared to live-attenuated and whole-inactivated virus vaccines. One reason is the lack of costimulatory signals provided by various components of live-attenuated and whole-inactivated vaccines. Here we improved the immunogenicity of the HIV-1 envelope glycoproteins (Env) by direct fusion to a costimulatory molecule, CD40 ligand (CD40L), which we term 'cis-adjuvant'. The rationale was to target the antigen directly to dendritic cells (DC) and B cells, while at the same time activating these cells.